Hospital

Recently announced trial results demonstrate the efficacy of the biologic in multiple disease indications.

It is more important than ever to have pharmacists and pharmacy professionals practicing at the top of their license to assist patients in pharmacy deserts.

Health system pharmacies can enhance operational and financial performance by leveraging key performance indicators, data-driven tools, and automation, ultimately supporting the broader health system’s adaptability and growth within an evolving health care landscape.

Pharmacists play a critical role in treating patients with breast cancer and can help address their social determinant of health challenges.

In children aged 12, 18, and 24 months, there was no association between maternal COVID-19 exposure and abnormal scores on a neurodevelopment screening.

Opioid stewardship coordinator Stephanie Abel, PharmD, BCPS, discusses initiatives such as increasing naloxone access, refining pain management protocols, and addressing stigma around opioid use disorder, highlighting the importance of clear goals and emotional intelligence for effective stewardship programs.

Martha Rumore, PharmD, Esq, discusses the legal and regulatory complexities surrounding tirzepatide compounding following FDA’s removal of the drug from the shortage list, which prompted a lawsuit and led to ongoing uncertainty for 503A and 503B facilities regarding enforcement discretion and future compounding restrictions.

Approximately 15% of patients with polycythemia vera will progress to myelofibrosis.

ASHP investigators determined the severity and impact of ongoing drug shortages, with approximately 99% of respondents reporting that they experienced a shortage.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Following lung cancer diagnosis, adjusting lifestyle habits can improve treatment responses.

Further efforts may be required to urge eligible members of the public to get screened for lung cancer.

Patients with hereditary angioedema who received sebetralstat earlier had faster complete resolution of their attacks.

Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.

Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.

Findings suggest further need to educate the public on receiving an indicated vaccine as we approach peak respiratory syncytial virus (RSV) season.

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

Stephanie Y. Crawford, PhD, MPH, highlights the expanded roles of pharmacists in clinical and non-clinical settings and their increased role in patient care, sharing personal experiences where pharmacists have been instrumental in supporting her family's health needs.

Though auto-injectors are still considered an appropriate first-line treatment for anaphylaxis, limited evidence exists surrounding their effectiveness in preventing fatal anaphylaxis.

The approval marks the first and only abuse-deterrent immediate release oxycodone formulation.

Apalutamide is a hormone therapy indicated for men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Investigators found that electronic letter reminders were most effective for older individuals, those who were unvaccinated in the preceding season, those with cardiovascular disease, and those with diabetes.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

NCCN recommends ribociclib as a preferred CDK4/6 inhibitor adjuvant therapy for patients with HR+/HER2- EBC in combination with an aromatase inhibitor.

Utilizing data from the CHAMPION MG trial, investigators found that many patients had responded to ravulizumab and returned to daily activities within 2 weeks.

Historically, colchicine has been used primarily in the management of gout; however, in 2023, the FDA approved Lodoco, a newly marketed colchicine product, for the management of cardiovascular disease.